Because the Generation Program enrolls people at risk of developing AD based on age and genotype (presence of the APOE4 gene), we investigated the ability of CNP520 to inhibit Aβ40 generation preclinically in the APOE4‐TR mouse model, in which the mouse Apoe gene is replaced by the human APOE4 gene (Castellano et al, 2011). This evidence concerns the gene APOE and Alzheimer disease.